Sprifermin for Treatment of Osteoarthritis: Recombinant Fibroblast Growth Factor 18 as a Possible Disease-Modifying Knee Osteoarthritis Drug.

Martin Jakab; Tobias Kiesslich; Antje van der Zee-Neuen; Wirth; W; Markus Ritter

Sprifermin for Treatment of Osteoarthritis: Recombinant Fibroblast Growth Factor 18 as a Possible Disease-Modifying Knee Osteoarthritis Drug.

Martin Jakab^* (First author)
, Tobias Kiesslich (Co-author)
, Antje van der Zee-Neuen (Co-author)
, Wirth
, W
, Markus Ritter

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Original language	English
Pages (from-to)	18-40
Journal	Paracelsus Proceedings of Experimental Medicine
Issue number	2
Publication status	Published - 2023

Cite this

@article{1162118848ed4d2ebc9230bbcc0a986b,

title = "Sprifermin for Treatment of Osteoarthritis: Recombinant Fibroblast Growth Factor 18 as a Possible Disease-Modifying Knee Osteoarthritis Drug.",

author = "Martin Jakab and Tobias Kiesslich and \{van der Zee-Neuen\}, Antje and Wirth and W and Markus Ritter",

note = "van der Zee-Neuen Ritter: Gastein Research Institute, Paracelsus Medical University, Salzburg, Austria. van der Zee-Neuen Ritter: Institute of Nursing Science and Practice, Paracelsus Medical University, Salzburg, Austria. Wirth: Institute of Anatomy and Cell Biology, Paracelsus Medical University, Salzburg, Austria",

year = "2023",

language = "English",

pages = "18--40",

journal = "Paracelsus Proceedings of Experimental Medicine",

issn = "2750-6584",

number = "2",

}

Sprifermin for Treatment of Osteoarthritis: Recombinant Fibroblast Growth Factor 18 as a Possible Disease-Modifying Knee Osteoarthritis Drug. / Jakab, Martin (First author); Kiesslich, Tobias (Co-author); van der Zee-Neuen, Antje (Co-author) et al.
In: Paracelsus Proceedings of Experimental Medicine, No. 2, 2023, p. 18-40.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Sprifermin for Treatment of Osteoarthritis: Recombinant Fibroblast Growth Factor 18 as a Possible Disease-Modifying Knee Osteoarthritis Drug.

AU - Jakab, Martin

AU - Kiesslich, Tobias

AU - van der Zee-Neuen, Antje

AU - Wirth, null

AU - W, null

AU - Ritter, Markus

N1 - van der Zee-Neuen Ritter: Gastein Research Institute, Paracelsus Medical University, Salzburg, Austria. van der Zee-Neuen Ritter: Institute of Nursing Science and Practice, Paracelsus Medical University, Salzburg, Austria. Wirth: Institute of Anatomy and Cell Biology, Paracelsus Medical University, Salzburg, Austria

PY - 2023

Y1 - 2023

M3 - Review article

SN - 2750-6584

SP - 18

EP - 40

JO - Paracelsus Proceedings of Experimental Medicine

JF - Paracelsus Proceedings of Experimental Medicine

IS - 2

ER -